Clinical Neuroscience Solutions, Inc.

The trials here

What the 29 trials at this site are about, from their registry records.

Conditions

• High blood pressure5 trials
• Depression4 trials
• Atopic dermatitis (eczema)2 trials
• Migraine2 trials
• Obstructive sleep apnoea2 trials
• Type 2 diabetes2 trials
• Bipolar disorder1 trial
• Obesity1 trial

Phase

• Phase 214 trials
• Phase 311 trials
• Phase 2/32 trials
• Phase 42 trials

Status

• Completed16 trials
• Active, not recruiting6 trials
• Recruiting2 trials
• Terminated2 trials
• Enrolling by invitation1 trial
• Not yet recruiting1 trial
• Withdrawn1 trial

Lead sponsor

• Eli Lilly and Company3 trials
• Mineralys Therapeutics Inc.3 trials
• Otsuka Pharmaceutical Development & Commercialization, Inc.3 trials
• Pfizer3 trials
• Apnimed2 trials
• and 13 more

Running trials

• Not yet recruiting

  A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes

  NCT07881432· Phase 3· Eli Lilly and Company· Source

  Contact: Lisa Usdan (principal investigator)

• Recruiting

  An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.

  NCT07543120· Phase 2· Novartis Pharmaceuticals· Source

  Contact: Melissa Flowers

• Active, not recruiting

  A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients

  NCT06857955· Phase 2· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)

  NCT06741228· Phase 3· Definium Therapeutics US, Inc.· Source

• Active, not recruiting

  A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

  NCT06625060· Phase 2· Ipsen· Source

• Enrolling by invitation

  Continuation Protocol for Obstructive Sleep Apnea (OSA)

  NCT06566820· Phase 3· Apnimed· Source

• Recruiting

  Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD

  NCT04781140· Phase 4· Supernus Pharmaceuticals, Inc.· Source

  Contact: Olivia Elbaum

• Active, not recruiting

  A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

  NCT05995964· Phase 2· Pfizer· Source

• Active, not recruiting

  Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

  NCT05968430· Phase 3· Mineralys Therapeutics Inc.· Source

• Active, not recruiting

  Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)

  NCT02736656· Phase 3· Supernus Pharmaceuticals, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• High blood pressure1 recruiting
• Obesity1 recruiting
• Obstructive sleep apnoea1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients

  NCT06836063· Phase 2· Suven Life Sciences Limited· Source

• Completed

  A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder

  NCT06817356· Phase 2· Eli Lilly and Company· Source

• Recruiting

  Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

  NCT06547489· Phase 2· Syndeio Biosciences, Inc· Source

  Contact: Karen Raudibaugh

• Terminated

  Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years With ADHD

  NCT06431256· Phase 3· Ironshore Pharmaceuticals and Development, Inc· Source

• Completed

  Study That Tests AD109 in Patients Taking GLP-1 Drugs

  NCT06400615· Phase 2· Apnimed· Source

• Completed

  Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

  NCT06153693· Phase 3· Mineralys Therapeutics Inc.· Source

• Completed

  A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

  NCT06045221· Phase 3· Eli Lilly and Company· Source

• Completed

  Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301

  NCT05286762· Phase 3· Cingulate Therapeutics· Source

• Completed

  ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder

  NCT05749055· Phase 2· Engrail Therapeutics INC· Source

• Completed

  A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

  NCT05769608· Phase 2· Mineralys Therapeutics Inc.· Source

• Completed

  A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder

  NCT05593029· Phase 2· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• Completed

  Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder

  NCT05536414· Phase 2· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• Completed

  A Study of JNJ-55308942 in the Treatment of Bipolar Depression

  NCT05328297· Phase 2· Janssen Pharmaceutica N.V., Belgium· Source

• Completed

  A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.

  NCT05279313· Phase 3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• Completed

  A Study of JZP150 in Adults With Posttraumatic Stress Disorder

  NCT05178316· Phase 2· Jazz Pharmaceuticals· Source

• Terminated

  A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

  NCT04804033· Phase 2/3· Pfizer· Source

• Completed

  A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

  NCT04085172· Phase 4· Shire· Source

• Completed

  Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

  NCT03422822· Phase 3· Pfizer· Source

• Completed

  Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder

  NCT03299166· Phase 2/3· Biohaven Pharmaceuticals, Inc.· Source